M

Madrigal Pharmaceuticals

D
MDGL
USD
14.55
(4.2788%)
Market Closed
29,246.00
Volume
-27.26
EPS
-
Div Yield
-13.888454
P/E
7,699,315,264.20
Market Cap
Today
4.8368%
1 Week
36.574%
1 Month
65.030%
6 Months
63.027%
12 Months
132.983%
Year To Date
53.010%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
V
VKTX
2.97
(4.5075%)
USD
C
CRBP
-0.36
(-1.9027%)
USD
ALNY
ALNY
4.735
(1.7707%)
USD
A
ARWR
0.055
(0.2579%)
USD
MRNA
MRNA
-0.985
(-1.921%)
USD
A
AGIO
3.39
(6.5698%)
USD
C
CRSP
1.15
(2.2656%)
USD
E
EDIT
-0.11
(-3.3537%)
USD
N
NTLA
-0.05
(-0.3113%)
USD

Title:
Madrigal Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Do you need help or have a question?
Contact Us